We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase I Study of High-Dose Continuous-Infusion Recombinant Interleukin-2 and Autologous Lymphokine-Activated Killer Cells in Patients With Metastatic or Unresectable Malignant Melanoma and Renal Cell Carcinoma.
- Authors
Gaynor, Ellen R.; Weiss, Geoffrey R.; Margolin, Kim A.; Aronson, Frederick R.; Sznol, Mario; Demchak, Paul; Grima, Kathleen M.; Fisher, Richard I.; Boldt, David H.; Doroshow, James H.; Bar, Michael H.; Hawkins, Michael J.; Mier, James W.; Caliendo, Geralyn
- Abstract
The current study was undertaken to determine the maximum tolerated dose of recombinant interleukin-2 (rIL-2) that could be administered as a continuous infusion in conjunction with autologous lymphokine-activated killer (LAK) cells. All 55 patients in this study received a priming dose of rIL-2 of 1.0 mg/m per day given as a continuous infusion over 4.5 days. Patients later received (days 11–16) one of three doses of rIL-2 per day (1.0, 1.25, or 1.50 mg/m) in conjunction with LAK cells given on days 11, 12, and 14. Because of unacceptable toxicity occurring early in the LAK cell phase of therapy at the rIL-2 dose level of 1.50 mg/m, we concluded that the maximum tolerated dose of rIL-2 given as a continuous infusion with LAK cells is 1.25 mg/m per day. [J Natl Cancer Inst 82: 1397–1402, 1990]
- Publication
JNCI: Journal of the National Cancer Institute, 1990, Vol 82, Issue 17, p1397
- ISSN
0027-8874
- Publication type
Article